Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2006-02-28
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000
Reexamination Certificate
active
07005434
ABSTRACT:
The present invention relates to novel compounds and the treatment of mammalian diseases in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.
REFERENCES:
patent: 5945431 (1999-08-01), Jin et al.
patent: 6025489 (2000-02-01), Davey et al.
patent: WO 96/15128 (1996-05-01), None
patent: WO 97/34894 (1997-09-01), None
patent: WO 99/09030 (1999-02-01), None
patent: WO 99/29318 (1999-06-01), None
patent: WO 96/61444 (1999-12-01), None
Thompson, A.M., et al., “3-(3,5-Dimethoxyphenyl)-1,6-Naptthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosone kinase”, (2000), J. Med. Chem.,vol. 43, pp. 4200-4211.
Davis Zinna Northington
Kellerman James C.
Kinzig Charles M.
SB Corporation
Venetianer Stephen
LandOfFree
Compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668481